News | March 05, 2014

Study Shows Gamma Knife Helps Patients with Trigeminal Neuralgia

Radiation Therapy Gamma Knife Stereotactic Radiosurgery

March 5, 2014 — Research by Beaumont Health System radiation oncologists and neurosurgeons found that symptoms of trigeminal neuralgia (TN) were reduced in those treated with Gamma Knife stereotactic radiosurgery. The results were published in the February issue of the journal Clinical Neurology and Neurosurgery.

TN is a disorder of the trigeminal nerve, which is responsible for feeling in the face. In most cases, the facial pain is caused by a blood vessel pressing on the nerve. It is believed that TN is caused by deterioration of the protective covering of the trigeminal nerve.

"The Gamma Knife is not actually a knife," says Inga Grills, M.D., radiation oncologist, Beaumont Hospital, Royal Oak and associate professor, Oakland University William Beaumont School of Medicine. "Gamma Knife stereotactic radiosurgery is a nonsurgical technique that precisely delivers a high dose of radiation to a targeted area. It sends more than 200 beams of gamma radiation, while the low intensity of the individual beams avoids causing damage to the surrounding tissues."

Principal investigator Grills and a team of Beaumont researchers analyzed data of 149 patients who were treated with Gamma Knife Stereotactic Radiosurgery (GK SRS). Following the treatment, patients were evaluated at about two weeks, then every three to six months. Patients reported if they experienced normal, decreased or no facial pain. Researchers concluded GK SRS provides acceptable relief for those with TN, especially those who are not suitable or have failed medical or surgical treatments.

"This study demonstrates patients with severe facial pain caused by trigeminal neuralgia will experience less discomfort after Gamma Knife Stereotactic Radiosurgery,” Grills said. “They can resume daily activities such as brushing their teeth, washing their face and even smiling, without the unbearable sensation that is often caused by this condition.”

Approximately 150,000 people are diagnosed with TN every year, according to the American Association of Neurological Surgeons. Women over the age of 50 are among those who are most commonly diagnosed. Those at risk are people with high-blood pressure or with multiple sclerosis.

For more information: http://www.journals.elsevier.com/clinical-neurology-and-neurosurgery

Related Content

RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...